The U.S. Food and Drug Administration says that Accord Healthcare is recalling One lot (Lot PW05264 - 46632 Bottles, NDC 16729-182-01) of Hydrochlorothiazide Tablets USP, 12.5 mg.
A pair of nationwide recalls, including tablets from different brand names and manufacturers, say that patients could face risky reactions or increase their cancer risk by taking unsafe or incorrect medication. This can result in "adverse events that range from limited health consequences to life-threatening situations in certain individuals", the FDA said in a statement.
Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
To date, the drugmaker has not received reports of adverse events in connection with the labeling mix-up.
Frank Field: Labour MP says anti-Semitism is 'more than tolerated' in party
The remarks comes after his constituency party delivered a no-confidence vote against him after he sided with the government in a series of Brexit votes.
Hydrochlorothiazide 12.5 mg pills are orange circles with an "H" on one side and a "1" on the other.
Accord said those taking the drug run the risk of having too much potassium, which could be life-threatening for certain people. Consumers are urged to report any drugs that do not match that description, or check with their pharmacist.
Not all drugs containing valsartan are being recalled, but this week the FDA expanded the list of drugs being recalled. Hydrochlorothiazide is veteran to deal with high blood strain.